Metabasis Therapeutics, Inc.

Gensia, Inc.

Biocryst, Inc.

Biocryst Pharmaceuticals, Inc.

Viking Therapeutics, Inc.

Ciba-geigy Corporation

Merck Sharp + Dohme Corp.

Sankyo Company, Limited

Gensia Sicor Inc.

John A., Iii Secrist

Mark D. Erion

Steven E. Ealick

John A. Montgomery

Mark D Erion

K Raja Reddy

Serge H Boyer

Qun Dang

Bheemarao G Ugarkar

Srinivas Rao Kasibhatla

M Rami Reddy

John A Montgomery

John A Secrist, Iii

Brett C Bookser

Steve E Ealick

Nicholas Brian Raffaele

Edward D Robinson

Wayne C Guida

Angelo J Castellino

Scott J Hecker

Venkat Reddy Mali

Clinton E Browne

Hongjian Jiang

Gerard Robert Scarlato

Jeff Stebbins

Jorge E Gomez Galeno

Harry E Gruber

Feng Tian

Brian Lian

Rochelle Hanley

G Sridhar Prasad

Wenyu Li

Misha Dinerman

Paul D Van Poelje

Shri Niwas

Stephane De Lombaert

Edward Earl Cable

David A Bullough

Scott D Edmondson

Toshihiko Fujiwara

Zhuyan Guo

Santhosh Francis Neelamkavil

Anthony K Ogawa

Weiguo Liu

Jiafang He

Rudrajit Mal

Ernest K Metzner

Kevin M Mullane

Gary S Firestein

Ellen K Vande Bunte

Michael Matelich

Mali Venkat Reddy

Leonard P Miller

Joseph J Kopcho

Atul Agurwal

Atul Agarwal

Michael C Matelich

Steven E Ealick

Iii Secrist John A

Santosh Neelamkavil

Michael G Matelich

Reddy K Raja

Methods useful for treating X-linked adrenoleukodystrophy are provided.

Use of thyroid beta-agonists

The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

Thyromimetics for the treatment of fatty liver diseases

This invention pertains to the use of fused bicycle heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof

A thyroid hormone receptor agonist and its use in the treatment of a disease associated thyroid hormone receptor beta are described. The compound can be effective in lowering cholesterol with minimum or no adverse effects on the heart or thyroid hormone axis.

Thyroid hormone receptor agonist and use thereof

The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Activators of glucokinase

The invention pertains to the use of compounds represented by the formula, Q-G-G-G-G-Z, where Q is  The compounds can be used as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes.

Factor XIa inhibitors

The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohdroxy pridines or primidines as diacylglycerol O-acyltransferase 1 DGAT-1 inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinase activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.

Phosphorus-containing prodrugs

Growing community of inventors

Del Mar, CA, United States of America

Mark D Erion